OTC Prilosec Risk/Benefit Ratio Relative To Current OTCs Questioned By Andrx
This article was originally published in The Tan Sheet
Executive Summary
Uncertainties about the safety and efficacy of OTC Prilosec (omeprazole 20 mg) combined with "the relative effectiveness" of currently available nonprescription acid-reducers, should cause FDA to deny Procter & Gamble/AstraZeneca's switch NDA, Andrx says in a Nov. 20 citizen petition
You may also be interested in...
Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change
Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change
Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change